My watch list  

18 Current news about the topic umbilical cord blood


You can refine your search further. Select from the filter options on the left to narrow down your results.

Amylon Therapeutics wins Startup Slam Competition at BIO-Europe® Berlin

Startup Slam sponsor Johnson & Johnson Innovation recognise high calibre of diverse European entries


Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the ...


image description
Attacking tumors from the inside

A group of immune cells can infiltrate, deliver viral vectors and destroy tumor cells


The targeted delivery of drugs directly into cancer cells is becoming an increasingly common method of ensuring more accurate, safer cancer treatments. Scientists are now exploring the concept of using specially-created groups of immune cells to carry biologics – drugs derived from natural ...


Stowers scientists successfully expand bone marrow-derived stem cells in culture


All stem cells — regardless of their source — share the remarkable capability to replenish themselves by undergoing self-renewal. Yet, so far, efforts to grow and expand scarce hematopoietic (or blood-forming) stem cells in culture for therapeutic applications have been met with limited ...


image description
Device could improve harvest of stem cells from umbilical cord blood


Johns Hopkins graduate students have invented a system to significantly boost the number of stem cells collected from a newborn's umbilical cord and placenta, so that many more patients with leukemia, lymphoma and other blood disorders can be treated with these valuable cells.The prototype is ...


VITA 34 International AG: VITA 34 plans further growth in 2011 and international expansion

Sales forecast of more than 18m Euro for 2011


The VITA 34 International AG wants to continue its growth in the current business year 2011 and aims at increasing the revenue from approximately 17m Euro in 2010 to more than 18m Euro. It is also intended to further increase the number of storages. With 11,038 umbilical cord blood storages in ...


VITA 34 and Hannover Medical School start project on iPS cells


VITA 34 International AG starts a joint research project on the production of so-called induced pluripotent stem cells (iPS cells) from umbilical cord blood in cooperation with the Hannover Medical School (MHH). In this project, VITA 34 and a MHH team under management of Prof. Dr. Ulrich Martin ...


VITA 34 has taken over majority in Spanish partner Secuvita


The VITA 34 International AG tightens its presence in the Spanish market and is now the indirect holder of 51.62 percent of the shares in the Spanish corporation Secuvita, S.L. by having taken over all of the company shares of the Novel Pharma S.L.. A purchase price at the amount of about 3 ...


Newly identified growth factor promotes stem cell growth, regeneration


Scientists at Duke University Medical Center have identified a new growth factor that stimulates the expansion and regeneration of hematopoietic (blood-forming) stem cells in culture and in laboratory animals. The discovery, appearing in the journal Nature Medicine , may help researchers overcome ...


First successful use of expanded umbilical-cord blood units to treat leukemia


Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers. In a study published in Nature Medicine , Colleen Delaney, M.D., and colleagues describe ...


VITA 34: Positive Results in Q2 2009


VITA 34 International AG, the parent company of the umbilical cord blood bank in the German-speaking countries, VITA 34, has returned to profitability in the second quarter of 2009. The earnings before interest and taxes (EBIT) improved to more than EUR 16k following a loss of EUR 0.8 million in ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE